Results 81 to 90 of about 70,369 (254)

Temozolomide in the management of dopamine agonist-resistant prolactinomas

, 2012
Background  The majority of prolactinomas respond to dopamine agonist therapy, but a proportion are resistant, requiring other treatments including surgery and/or radiotherapy.
King, A. P., Dworakowska, D., Thomas, N. W., Lipscomb, D., Buchanan, C. R., Barazi, S., Hampton, T., Gilbert, J. A., Aylwin , S. J. B., Riordan-Eva, P., Landau, D. B., Whitelaw, B. C.   +11 more
core   +1 more source

Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients

Annals of Saudi Medicine, 2012
BACKGROUND AND OBJECTIVES: Currently, radiotherapy with concomitant and adjuvant temozolomide has become the standard treatment for glioblastoma. The purpose of this study was to report our experience with radiation plus concomitant temozolomide in 116 ...
Nilgun Ozbek Okumus, Bilge Gursel, Deniz Meydan, Ozge Ozdemir, Eylem Odabası, Guzin Gonullu   +5 more
doaj   +1 more source

Glycosylated dendrimer nanoamplifiers hijack DNA damage‐immune crosstalk for enhanced dual‐track therapy of orthotopic glioblastoma

BMEMat, EarlyView.
A glycosylated dendrimer nanoamplifier hijacks DNA damage‐immune crosstalk for enhanced radio‐immunotherapy of glioblastoma. The responsive release of demethylcantharidin simultaneously blocks repair‐mediated resistance by inhibiting DNA repair and overcomes adaptive immune resistance.
Cong Song, Binghan Liu, Junjie Liu, Ce Li, Wenqing Man, Xurui Sun, Chang Yuan, Yanjun Wang, Hong Pan, Shuanglian Wang, Zhiming Zheng   +10 more
wiley   +1 more source

Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations

, 2009
Margarita García,1 Ana Clopés,2 Jordi Bruna,3 María Martínez,4 Eduard Fort,2 Miguel Gil51Clinical Research Unit, Institut Català d’Oncologia-IDIBeLL, L’Hospitalet, Barcelona ...
Ana Clopés, Margarita García, Jordi Bruna   +2 more
core  

Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

iScience
Summary: Resistance to chemotherapies such as temozolomide is a major hurdle to effectively treat therapy-resistant glioblastoma. This challenge arises from the activation of phosphatidylinositol 3-kinase (PI3K), which makes it an appealing therapeutic ...
Kevin J. Pridham, Kasen R. Hutchings, Patrick Beck, Min Liu, Eileen Xu, Erin Saechin, Vincent Bui, Chinkal Patel, Jamie Solis, Leah Huang, Allison Tegge, Deborah F. Kelly, Zhi Sheng   +12 more
doaj   +1 more source

In vitro therapy against glioblastoma cells by 3-Dezaneplanocin-A, panobinostat, and temozolomide

Glioma, 2018
Background: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. Current treatment against this tumor consists of maximal surgical resection without threatening the patient's life, followed by a treatment with temozolomide, with or ...
Javier de la Rosa, Alejandro Urdiciain, Bárbara Meléndez, Juan A Rey, Miguel A Idoate, Javier S Castresana   +5 more
doaj   +1 more source

Perampanel as add‐on in high‐grade glioma–related epilepsy: Seizure control and QoL in a prospective, multicenter, real‐world 6‐month follow‐up study

Epilepsia Open, EarlyView.
Abstract Objective High‐grade astrocytomas, including glioblastomas, are aggressive brain tumors with poor prognosis and a 5‐year survival below 7%. Seizures affect up to 75% of glioma patients, especially in low‐grade tumors but also in high‐grade cases.
Matteo Impellizzeri, Paolo Paone, Giada Pauletto, Annacarmen Nilo, Simone Beretta, Andrea Salmaggi, Stefano Consoli, Stefano Quadri   +7 more
wiley   +1 more source

Progress of temozolomide in the treatment of recurrent high-grade gliomas

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
High-grade gliomas are central nervous system malignancies which are difficult to treat. Surgery, temozolomide combined with radiotherapy postoperatively and adjuvant chemotherapy with temozolomide have been established as the standard treatment options ...
Jin-duo LI, Rong JIANG, Jin-huan WANG, Bin WANG, Chun-hua MA, Li-wei SUN, Yuan LÜ, Guo-fang HOU   +7 more
doaj  

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

International Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T. Maich, Alisha Anand, Oliver Y. Tang, Minomi K. Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna, Benjamin Brakel, Vassil Dimitrov, Zoya Tabunshchyk, Katie Chan, Kevin R. Brown, Parvez Vora, Donald M. O'Rourke, Zev A. Binder, Chitra Venugopal, Jason Moffat, Sheila K. Singh   +22 more
wiley   +1 more source

Long-term use of temozolomide : could you use temozolomide safely for life in gliomas?

, 2009
Long-term use of temozolomide : could you use temozolomide safely for life in ...
D Bell (8736168), H Wheeler (13311603), Mustafa Khasraw (13078896)   +2 more
core